CLINICAL TRIALS PROFILE FOR NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
✉ Email this page to a colleague
All Clinical Trials for NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01344369 ↗ | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the relative bioavailability of a test formulation of norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablets (Teva Pharmaceuticals, USA) compared to the reference listed product, FEMCON® Fe (norethindrone/ethinyl estradiol and ferrous fumarate) 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott) under fed conditions in healthy, non-tobacco using, adult female subjects. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Condition Name
Clinical Trial Locations for NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Trials by Country
Clinical Trial Progress for NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Sponsor Name